Literature DB >> 33862140

Free sialic acid storage disorder: Progress and promise.

Marjan Huizing1, Mary E Hackbarth2, David R Adams2, Melissa Wasserstein3, Marc C Patterson4, Steven U Walkley5, William A Gahl2.   

Abstract

Lysosomal free sialic acid storage disorder (FSASD) is an extremely rare, autosomal recessive, neurodegenerative, multisystemic disorder caused by defects in the lysosomal sialic acid membrane exporter SLC17A5 (sialin). SLC17A5 defects cause free sialic acid and some other acidic hexoses to accumulate in lysosomes, resulting in enlarged lysosomes in some cell types and 10-100-fold increased urinary excretion of free sialic acid. Clinical features of FSASD include coarse facial features, organomegaly, and progressive neurodegenerative symptoms with cognitive impairment, cerebellar ataxia and muscular hypotonia. Central hypomyelination with cerebellar atrophy and thinning of the corpus callosum are also prominent disease features. Around 200 FSASD cases are reported worldwide, with the clinical spectrum ranging from a severe infantile onset form, often lethal in early childhood, to a mild, less severe form with subjects living into adulthood, also called Salla disease. The pathobiology of FSASD remains poorly understood and FSASD is likely underdiagnosed. Known patients have experienced a diagnostic delay due to the rarity of the disorder, absence of routine urine sialic acid testing, and non-specific clinical symptoms, including developmental delay, ataxia and infantile hypomyelination. There is no approved therapy for FSASD. We initiated a multidisciplinary collaborative effort involving worldwide academic clinical and scientific FSASD experts, the National Institutes of Health (USA), and the FSASD patient advocacy group (Salla Treatment and Research [S.T.A.R.] Foundation) to overcome the scientific, clinical and financial challenges facing the development of new treatments for FSASD. We aim to collect data that incentivize industry to further develop, obtain approval for, and commercialize FSASD treatments. This review summarizes current aspects of FSASD diagnosis, prevalence, etiology, and disease models, as well as challenges on the path to therapeutic approaches for FSASD.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Hypomyelination; Infantile sialic acid storage disorder; Lysosomal membrane transporter; N-acetylneuraminic acid; SLC17A5; Salla disease; Sialic acid

Mesh:

Substances:

Year:  2021        PMID: 33862140      PMCID: PMC8175077          DOI: 10.1016/j.neulet.2021.135896

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  128 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  MENDELIAN PROPORTIONS IN A MIXED POPULATION.

Authors:  G H Hardy
Journal:  Science       Date:  1908-07-10       Impact factor: 47.728

Review 3.  Mammalian sialidases: physiological and pathological roles in cellular functions.

Authors:  Taeko Miyagi; Kazunori Yamaguchi
Journal:  Glycobiology       Date:  2012-02-28       Impact factor: 4.313

4.  New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.

Authors:  Maria R Gigliobianco; Piera Di Martino; Siyuan Deng; Cristina Casadidio; Roberta Censi
Journal:  Curr Pharm Des       Date:  2019       Impact factor: 3.116

5.  [Description of a new type of melituria, called sialuria].

Authors:  J Montreuil; G Biserte; G Strecker; G Spik; G Fontaine; J P Farriaux
Journal:  Clin Chim Acta       Date:  1968-07       Impact factor: 3.786

6.  Vesicular uptake of N-acetylaspartylglutamate is catalysed by sialin (SLC17A5).

Authors:  Julia Lodder-Gadaczek; Volkmar Gieselmann; Matthias Eckhardt
Journal:  Biochem J       Date:  2013-08-15       Impact factor: 3.857

7.  Clinical course and biochemistry of sialuria.

Authors:  G M Enns; R Seppala; T J Musci; K Weisiger; L D Ferrell; D A Wenger; W A Gahl; S Packman
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

Review 8.  Osteopetroses, emphasizing potential approaches to treatment.

Authors:  Anna Teti; Michael J Econs
Journal:  Bone       Date:  2017-02-04       Impact factor: 4.398

9.  Linkage disequilibrium utilized to establish a refined genetic position of the Salla disease locus on 6q14-q15.

Authors:  J Schleutker; A P Laine; L Haataja; M Renlund; J Weissenbach; P Aula; L Peltonen
Journal:  Genomics       Date:  1995-05-20       Impact factor: 5.736

10.  Cystinosin is a Component of the Vacuolar H+-ATPase-Ragulator-Rag Complex Controlling Mammalian Target of Rapamycin Complex 1 Signaling.

Authors:  Zuzanna Andrzejewska; Nathalie Nevo; Lucie Thomas; Cerina Chhuon; Anne Bailleux; Véronique Chauvet; Pierre J Courtoy; Marie Chol; Ida Chiara Guerrera; Corinne Antignac
Journal:  J Am Soc Nephrol       Date:  2015-10-08       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.